Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2025-12-25 @ 8:16 PM
Study NCT ID:
NCT03443869
Status:
COMPLETED
Last Update Posted:
2023-07-28
First Post:
2018-02-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-05-03
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-05
Completion Date Type:
ACTUAL
First Submit Date:
2018-02-19
First Submit QC Date:
None
Study First Post Date:
2018-02-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-03-23
Results First Submit QC Date:
None
Results First Post Date:
2023-04-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-07-26
Last Update Post Date:
2023-07-28
Last Update Post Date Type:
ACTUAL